Therapeutic Strategy for Heart Failure with Reduced Ejection Fraction and Cardiac Amyloidosis
We sometimes encounter patients with systolic heart failure and cardiac amyloidosis. Neurohormonal blockers are guideline-directed medical therapy for those with systolic heart failure. However, its implication among the above cohort remains controversial. Of 3 patients with systolic heart failure a...
Gespeichert in:
| Veröffentlicht in: | International Heart Journal 2022/03/30, Vol.63(2), pp.408-410 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 410 |
|---|---|
| container_issue | 2 |
| container_start_page | 408 |
| container_title | International Heart Journal |
| container_volume | 63 |
| creator | Imamura, Teruhiko Izumida, Toshihide Nakamura, Makiko Kinugawa, Koichiro |
| description | We sometimes encounter patients with systolic heart failure and cardiac amyloidosis. Neurohormonal blockers are guideline-directed medical therapy for those with systolic heart failure. However, its implication among the above cohort remains controversial. Of 3 patients with systolic heart failure and cardiac amyloidosis who we encountered, cardiac reverse remodeling was achieved in 2 patients who received neurohormonal blockers, whereas cardiac function remained unchanged in a patient not receiving neurohormonal blockers. Neurohormonal blockers might be keys to achieve cardiac reverse remodeling and favorable clinical outcomes even in patients with systolic heart failure and cardiac amyloidosis, although further larger-scale studies are required to validate our hypothesis. |
| doi_str_mv | 10.1536/ihj.21-664 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_2646156730</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2646156730</sourcerecordid><originalsourceid>FETCH-LOGICAL-c457t-742d28cbeef852edab91c3091605729841b7cca5f4eb06b34f1e1386932edc3b3</originalsourceid><addsrcrecordid>eNo9kE1Lw0AQhhdRbK1e_AGy4E1I3e80N6W0VigIWo-ybDaTdkPa1N0N0n9vbGsvMy_MwzvwIHRLyZBKrh7dqhoymiglzlCfcpElnGXZ-TEzrmQPXYVQESKoJOkl6nHJpUhl1kdfixV4s4U2Oos_ojcRljtcNh7PwPiIp8bVrQf84-IKv0PRWijwpAIbXbPBU28OwWwKPDa-cMbi5_WublzRBBeu0UVp6gA3xz1An9PJYjxL5m8vr-PneWKFTGOSClawkc0BypFkUJg8o5aTjCoiU5aNBM1Ta40sBeRE5VyUFCgfqYx3sOU5H6D7Q-_WN98thKirpvWb7qVmSigqVcpJRz0cKOubEDyUeuvd2vidpkT_mdSdSc2o7kx28N2xss3XUJzQf3Ud8HQAqhDNEk5AZ83ZGvZdimu2H_vO08mujNew4b_q1YXy</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2646156730</pqid></control><display><type>article</type><title>Therapeutic Strategy for Heart Failure with Reduced Ejection Fraction and Cardiac Amyloidosis</title><source>J-STAGE Free</source><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>Imamura, Teruhiko ; Izumida, Toshihide ; Nakamura, Makiko ; Kinugawa, Koichiro</creator><creatorcontrib>Imamura, Teruhiko ; Izumida, Toshihide ; Nakamura, Makiko ; Kinugawa, Koichiro</creatorcontrib><description>We sometimes encounter patients with systolic heart failure and cardiac amyloidosis. Neurohormonal blockers are guideline-directed medical therapy for those with systolic heart failure. However, its implication among the above cohort remains controversial. Of 3 patients with systolic heart failure and cardiac amyloidosis who we encountered, cardiac reverse remodeling was achieved in 2 patients who received neurohormonal blockers, whereas cardiac function remained unchanged in a patient not receiving neurohormonal blockers. Neurohormonal blockers might be keys to achieve cardiac reverse remodeling and favorable clinical outcomes even in patients with systolic heart failure and cardiac amyloidosis, although further larger-scale studies are required to validate our hypothesis.</description><identifier>ISSN: 1349-2365</identifier><identifier>EISSN: 1349-3299</identifier><identifier>DOI: 10.1536/ihj.21-664</identifier><identifier>PMID: 35354759</identifier><language>eng</language><publisher>Japan: International Heart Journal Association</publisher><subject>Amyloidosis ; Amyloidosis - complications ; Amyloidosis - drug therapy ; Congestive heart failure ; Heart ; Heart failure ; Heart Failure, Systolic ; Hemodynamics ; Humans ; Patients ; Stroke Volume ; Tafamidis ; Ventricular Dysfunction, Left</subject><ispartof>International Heart Journal, 2022/03/30, Vol.63(2), pp.408-410</ispartof><rights>2022 by the International Heart Journal Association</rights><rights>Copyright Japan Science and Technology Agency 2022</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c457t-742d28cbeef852edab91c3091605729841b7cca5f4eb06b34f1e1386932edc3b3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,1882,27923,27924</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35354759$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Imamura, Teruhiko</creatorcontrib><creatorcontrib>Izumida, Toshihide</creatorcontrib><creatorcontrib>Nakamura, Makiko</creatorcontrib><creatorcontrib>Kinugawa, Koichiro</creatorcontrib><title>Therapeutic Strategy for Heart Failure with Reduced Ejection Fraction and Cardiac Amyloidosis</title><title>International Heart Journal</title><addtitle>Int. Heart J.</addtitle><description>We sometimes encounter patients with systolic heart failure and cardiac amyloidosis. Neurohormonal blockers are guideline-directed medical therapy for those with systolic heart failure. However, its implication among the above cohort remains controversial. Of 3 patients with systolic heart failure and cardiac amyloidosis who we encountered, cardiac reverse remodeling was achieved in 2 patients who received neurohormonal blockers, whereas cardiac function remained unchanged in a patient not receiving neurohormonal blockers. Neurohormonal blockers might be keys to achieve cardiac reverse remodeling and favorable clinical outcomes even in patients with systolic heart failure and cardiac amyloidosis, although further larger-scale studies are required to validate our hypothesis.</description><subject>Amyloidosis</subject><subject>Amyloidosis - complications</subject><subject>Amyloidosis - drug therapy</subject><subject>Congestive heart failure</subject><subject>Heart</subject><subject>Heart failure</subject><subject>Heart Failure, Systolic</subject><subject>Hemodynamics</subject><subject>Humans</subject><subject>Patients</subject><subject>Stroke Volume</subject><subject>Tafamidis</subject><subject>Ventricular Dysfunction, Left</subject><issn>1349-2365</issn><issn>1349-3299</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo9kE1Lw0AQhhdRbK1e_AGy4E1I3e80N6W0VigIWo-ybDaTdkPa1N0N0n9vbGsvMy_MwzvwIHRLyZBKrh7dqhoymiglzlCfcpElnGXZ-TEzrmQPXYVQESKoJOkl6nHJpUhl1kdfixV4s4U2Oos_ojcRljtcNh7PwPiIp8bVrQf84-IKv0PRWijwpAIbXbPBU28OwWwKPDa-cMbi5_WublzRBBeu0UVp6gA3xz1An9PJYjxL5m8vr-PneWKFTGOSClawkc0BypFkUJg8o5aTjCoiU5aNBM1Ta40sBeRE5VyUFCgfqYx3sOU5H6D7Q-_WN98thKirpvWb7qVmSigqVcpJRz0cKOubEDyUeuvd2vidpkT_mdSdSc2o7kx28N2xss3XUJzQf3Ud8HQAqhDNEk5AZ83ZGvZdimu2H_vO08mujNew4b_q1YXy</recordid><startdate>20220330</startdate><enddate>20220330</enddate><creator>Imamura, Teruhiko</creator><creator>Izumida, Toshihide</creator><creator>Nakamura, Makiko</creator><creator>Kinugawa, Koichiro</creator><general>International Heart Journal Association</general><general>Japan Science and Technology Agency</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QP</scope></search><sort><creationdate>20220330</creationdate><title>Therapeutic Strategy for Heart Failure with Reduced Ejection Fraction and Cardiac Amyloidosis</title><author>Imamura, Teruhiko ; Izumida, Toshihide ; Nakamura, Makiko ; Kinugawa, Koichiro</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c457t-742d28cbeef852edab91c3091605729841b7cca5f4eb06b34f1e1386932edc3b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Amyloidosis</topic><topic>Amyloidosis - complications</topic><topic>Amyloidosis - drug therapy</topic><topic>Congestive heart failure</topic><topic>Heart</topic><topic>Heart failure</topic><topic>Heart Failure, Systolic</topic><topic>Hemodynamics</topic><topic>Humans</topic><topic>Patients</topic><topic>Stroke Volume</topic><topic>Tafamidis</topic><topic>Ventricular Dysfunction, Left</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Imamura, Teruhiko</creatorcontrib><creatorcontrib>Izumida, Toshihide</creatorcontrib><creatorcontrib>Nakamura, Makiko</creatorcontrib><creatorcontrib>Kinugawa, Koichiro</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Calcium & Calcified Tissue Abstracts</collection><jtitle>International Heart Journal</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Imamura, Teruhiko</au><au>Izumida, Toshihide</au><au>Nakamura, Makiko</au><au>Kinugawa, Koichiro</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Therapeutic Strategy for Heart Failure with Reduced Ejection Fraction and Cardiac Amyloidosis</atitle><jtitle>International Heart Journal</jtitle><addtitle>Int. Heart J.</addtitle><date>2022-03-30</date><risdate>2022</risdate><volume>63</volume><issue>2</issue><spage>408</spage><epage>410</epage><pages>408-410</pages><artnum>21-664</artnum><issn>1349-2365</issn><eissn>1349-3299</eissn><abstract>We sometimes encounter patients with systolic heart failure and cardiac amyloidosis. Neurohormonal blockers are guideline-directed medical therapy for those with systolic heart failure. However, its implication among the above cohort remains controversial. Of 3 patients with systolic heart failure and cardiac amyloidosis who we encountered, cardiac reverse remodeling was achieved in 2 patients who received neurohormonal blockers, whereas cardiac function remained unchanged in a patient not receiving neurohormonal blockers. Neurohormonal blockers might be keys to achieve cardiac reverse remodeling and favorable clinical outcomes even in patients with systolic heart failure and cardiac amyloidosis, although further larger-scale studies are required to validate our hypothesis.</abstract><cop>Japan</cop><pub>International Heart Journal Association</pub><pmid>35354759</pmid><doi>10.1536/ihj.21-664</doi><tpages>3</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1349-2365 |
| ispartof | International Heart Journal, 2022/03/30, Vol.63(2), pp.408-410 |
| issn | 1349-2365 1349-3299 |
| language | eng |
| recordid | cdi_proquest_journals_2646156730 |
| source | J-STAGE Free; MEDLINE; EZB-FREE-00999 freely available EZB journals |
| subjects | Amyloidosis Amyloidosis - complications Amyloidosis - drug therapy Congestive heart failure Heart Heart failure Heart Failure, Systolic Hemodynamics Humans Patients Stroke Volume Tafamidis Ventricular Dysfunction, Left |
| title | Therapeutic Strategy for Heart Failure with Reduced Ejection Fraction and Cardiac Amyloidosis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-08T14%3A58%3A59IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Therapeutic%20Strategy%20for%20Heart%20Failure%20with%20Reduced%20Ejection%20Fraction%20and%20Cardiac%20Amyloidosis&rft.jtitle=International%20Heart%20Journal&rft.au=Imamura,%20Teruhiko&rft.date=2022-03-30&rft.volume=63&rft.issue=2&rft.spage=408&rft.epage=410&rft.pages=408-410&rft.artnum=21-664&rft.issn=1349-2365&rft.eissn=1349-3299&rft_id=info:doi/10.1536/ihj.21-664&rft_dat=%3Cproquest_cross%3E2646156730%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2646156730&rft_id=info:pmid/35354759&rfr_iscdi=true |